Novartis’s JAK Inhibitor Fails In COVID, Raising Questions On Lilly Prospects
Adds To Puzzle Over JAK Inhibitors
The Phase III failure of ruxolotinib contrasts with encouraging results and emergency use authorization for Lilly’s JAK inhibitor baricitinib in combination therapy.
You may also be interested in...
Drugs for ARDS in COVID-19 have yielded mixed results in the clinic, with Boehringer Ingelheim pulling one from Phase II development earlier this month.
Drug fails to save lives in study and follows disappointments from Roche and Regeneron/Sanofi's IL-6 inhibitors.
Swiss biotech Molecular Partners will receive upfront payment of CHF60m, including equity.